There are currently 134 clinical trials in Eugene, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Research Institute, Willamette Valley Cancer Institute and Research Center, University of Oregon and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
NCT03918408
Recruiting
To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
11/09/2024
Locations: Pacific Clear Vision Institute, Eugene, Oregon
Conditions: Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Oncology Associates of Oregon, P.C., Eugene, Oregon
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Oncology Associates of Oregon, PC, Eugene, Oregon
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
Disrupting SDOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions
NCT06560866
Recruiting
The study will evaluate the effectiveness of the Just Care for Families program in preventing Oregon Department of Human Services (ODHS)-involved parents in rural communities from escalating opioid and/or methamphetamine use and mental health disorders by disrupting the associated social determinants of health (SDOH). In addition, investigators will examine the impacts of SDOH on Just Care treatment and the associated costs from the perspective of provider clinics delivering Just Care. Just Care... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/14/2024
Locations: Chestnut Health Systems, Eugene, Oregon
Conditions: Social Determinants of Health, Substance-Related Disorders
Register for Updates
Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction
NCT05860257
Recruiting
Adolescence is a developmental period of significant risk for anxiety, depressive symptoms, and suicidality, and the investigators propose to target key peer-based risk and protective factors using Cooperative Learning (CL). CL is a small-group instructional approach that can enhance peer relations and reduce peer-related risks, as well as promote academic engagement and achievement and reduce racial disparities. CL will be delivered with the aid of technology that automates the design and deliv... Read More
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
08/05/2024
Locations: U of Oregon, Eugene, Oregon
Conditions: Anxiety Depression, Suicidal Ideation
Register for Updates
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
NCT05830110
Recruiting
The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses... Read More
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
07/23/2024
Locations: Synergic Medical Technologies, Eugene, Oregon
Conditions: Parkinson's Disease
Register for Updates
Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function
NCT05684094
Recruiting
This research will use biobehavioral approaches to generate understanding about the linkages between stressful life events, sleep duration and timing, and alcohol use in young adults, with a long-term aim of developing effective preventative interventions for alcohol use disorders.
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
07/17/2024
Locations: Oregon Sleep Lab, Eugene, Oregon
Conditions: Alcohol Use Disorder
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Garden-fresh Foods and Gut Microbiomes
NCT06506786
Recruiting
The purpose of this research is to explore what types of microbes are present on garden-fresh versus store-bought fruits and vegetables, as well as how they might affect the human gut microbiome.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/16/2024
Locations: Institute for Health in the Built Environment, University of Oregon, Eugene, Oregon
Conditions: Gut Microbiome
Register for Updates
Essential Amino Acid Supplementation for Femoral Fragility Fractures
NCT06050668
Recruiting
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary i... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/15/2024
Locations: Slocum Center for Orthopedics & Sports Medicine, Eugene, Oregon
Conditions: Femoral Fracture, Fragility Fracture, Muscle Atrophy
Register for Updates
Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults
NCT06414993
Recruiting
Emerging adults (EAs; aged 18-26) are the highest-risk population for poly-substance use (misuse of more than one drug), compared to all other age groups and are the least-served population for substance use services. The overarching purpose of this pilot study is to assess whether an innovative services package, Launch, can reasonably work (is feasible) and whether providers and participants like it (acceptability). Launch works with both EAs and a supportive parent (or parental figure) and del... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Chestnut Health Systems, Eugene, Oregon
Conditions: Polysubstance Drug Use (Indiscriminate Drug Use)
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Oncology Associates Of Oregon, P.C., Eugene, Oregon
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates